Evidence map›Paper›PMID 41909046›Full record

ArticleFrontiers in nutrition2026

The impact of washed microbiota transplantation on serum gastric function markers: pepsinogen I, pepsinogen II, and Gastrin-17.

Youlin Song, Guoqian Liu, Juan Yang, Jiangyan Wang, Shuo Feng, Shenghua Lu, Zhichu Qin, Xingxiang He, Lei Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Youlin Song *Department of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Guoqian Liu *Department of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Juan YangDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Jiangyan WangDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Shuo FengDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Shenghua LuDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Zhichu QinDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xingxiang HeDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Lei WuDepartment of Gastroenterology/Microbiota Medicine, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Conventional treatment methods for gastric diseases have problems such as drug resistance and recurrence. This study aims to explore whether a new treatment method-Washed Microbiota Transplantation (WMT)-can improve gastric mucosal health. Methods: The clinical data of patients before and after WMT treatment were collected and analyzed, including serum gastric function markers: gastrin-17 (G-17), pepsinogen I (PGI), pepsinogen II (PGII), and the PGI/PGII ratio (PGR). Inflammatory biomarkers: C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6). Fresh fecal samples were collected at baseline and after WMT treatment and stored at -80 °C until analysis. Gut microbiota profiling was performed using 16S rRNA genes sequencing. Gastrointestinal symptom severity as measured by the Gastrointestinal Symptom Rating Scale (GSRS), and health-related quality of life assessed by the SF-36 physical and mental component summaries (PCS and MCS). The safety and tolerability of WMT were also assessed. Results: After WMT treatment, serum G-17 and PGI levels decreased significantly within the WMT group (both Conclusion: WMT was associated with improvements in gastric mucosal health, gut microbial abundance and diversity, accompanied by reduced inflammation, alleviated gastrointestinal symptoms, improved quality of life, and a favorable safety profile.

Indexed as

clinical efficacygastrointestinal disordergastrointestinal symptomsgut microbiotawashed microbiota transplantation

Identifiers

PMID41909046
PMCPMC13019745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.